During Monday’s Current trade, Shares of Diebold Inc (NYSE:DBD), gain 0.44% to $34.22.
Diebold, Incorporated (DBD) declared it is ongoing to shape its senior leadership structure and has eliminated the position of chief operating officer (COO). As a result, George S. Mayes Jr., executive vice president and COO, has left the company. Mayes, 56, joined Diebold in January 2005 as vice president, global manufacturing, and was named COO in January 2013.
As Diebold enhances its emphasis on growing services and software, the company has been implementing a more distributed leadership model at the senior level — allowing more decisions to be made closer to the customer — while leveraging new systems and processes to foster a sound global control environment.
Diebold, Incorporated provides financial self-service delivery, integrated services and software, and security systems primarily to the financial, commercial, retail, and other markets. The company operates in five segments: North America; Asia Pacific; Europe, Middle East and Africa; Latin America; and Brazil. It offers self-service technologies and services, counting automated teller machine (ATM) outsourcing, ATM security, deposit automation, recycling and payment terminals, and software.
Shares of Allstate Corp (NYSE:ALL), declined -0.01% to $68.95, during its current trading session.
Allstate Insurance becomes the first company to commit to a second Corporate-Startup Challenge from The Illinois Science & Technology Coalition, which matches large corporations with startups and emerging technology firms across Illinois. Allstate will host selected companies, provide feedback on their pitches and, ultimately, could engage the startups in future business endeavors.
Allstate was part of the first class of the Corporate-Startup Challenge in the summer of 2013. In that class, 22 companies were referred to Allstate’s portfolio, and 13 were selected to present for further evaluation. After the demonstration day, six companies were identified for additional diligence and one became an approved Allstate preferred vendor.
The Allstate Corporation, through its auxiliaries, engages in the property-liability insurance and life insurance businesses in the United States and Canada. The company’s Allstate Protection segment sells private passenger auto and homeowners insurance products under the Allstate, Encompass, Esurance brand names.
RSP Permian Inc (NYSE:RSPP), during its Monday’s current trading session gained 0.81% to $25.00.
RSP Permian, Inc(RSPP) declared that it will release its second quarter 2015 results after the New York Stock Exchange closes on Monday, August 3, 2015. In connection with the earnings release, RSP will host a conference call and webcast for investors on Tuesday, August 4, 2015 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time) to talk about the Company’s results for the quarter. Hosting the call will be Steve Gray, Chief Executive Officer, Zane Arrott, Chief Operating Officer, and Scott McNeill, Chief Financial Officer.
RSP Permian, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, development, and production of unconventional oil and associated liquids-rich natural gas reserves in the Permian Basin of West Texas. It owns interest in contiguous acreage blocks in the core of the Midland Basin, a sub-basin of the Permian Basin, primarily in the adjacent counties of Midland, Martin, Andrews, Dawson, Ector, and Glasscock.
Finally, Valeant Pharmaceuticals Intl Inc (NYSE:VRX), decreased -0.47%, to $257.00.
RedHill Biopharma Ltd. an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, counting gastrointestinal cancers, recently offered an update on its RHB-106 tasteless solid oral formulation bowel preparation development program under the worldwide exclusive license agreement with Salix Pharmaceuticals Ltd. (“Salix”), recently attained by Valeant Pharmaceuticals International, Inc. (“Valeant”) (VRX) (VRX).
Salix confirmed to RedHill that it continues the development of RHB-106. Salix further clarified to RedHill that the bowel purgative product referenced in Valeant’s second quarter 2015 financial results presentation1 as a failed toxicology screen is not RedHill’s RHB-106.
On February 27, 2014, RedHill and Salix reached an exclusive license agreement under which Salix attained the worldwide exclusive rights to RedHill’s RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments. Financial terms of the transaction comprised of an upfront payment to RedHill of $7 million, and an additional $5 million in subsequent milestone payments to RedHill. Salix also agreed to pay RedHill tiered royalties on net sales, ranging from low single digits up to low double digits.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
